The effect of human recombinant erythropoietin on the lipid peroxidation processes and antioxidant protection of the erythrocytes in patients with chronic kidney failure on hemodialysis

• Published in: Gematologiia i transfuziologiia Vol. 38; no. 3; p. 24
• Main Authors: Rud'ko, I A, Balashova, T S, Pokrovskiĭ, Iu A, Ermolenko, V M, Kubatiev, A A
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 01.03.1993
• Subjects: Adult; Antioxidants; Combined Modality Therapy; Drug Evaluation; Erythrocytes - drug effects; Erythrocytes - metabolism; Erythropoietin - therapeutic use; Humans; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - therapy; Lipid Peroxidation - drug effects; Malondialdehyde - blood; Middle Aged; Recombinant Proteins - therapeutic use; Renal Dialysis
• ISSN: 0234-5730

Twenty patients with terminal-stage chronic renal failure (CRF) underwent long-term hemodialysis. Ten of them (group 1) did not receive human erythropoietin (HEP), four patients (group 2) received HEP for 1 month, six patients (group 3) for 12 months. Group 3 patients exhibited a marked increase in Hb, hematocrit, red cell number, while serum Fe was reduced. MDA rose in group 1 by 34% (p < 0.05), in group 2 by 199% (p < 0.05), was normal in group 3. Red cell catalase and glutathione peroxidase activities were normal. The results evidence that 1-month HEP treatment enhances oxidant degradation of erythrocytic membrane lipids. Lipid peroxidation becomes normal to the end of 1-year HEP treatment despite low SOD activity. Application of HEP in CRF patients is advisable to combine with antioxidant modalities to intensify red cell resistance to hemodialysis.